Citius Pharmaceuticals’ (CTXR) “Hold” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research note issued to investors on Friday,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

Shares of CTXR stock opened at $0.13 on Friday. The company has a market cap of $24.13 million, a price-to-earnings ratio of -0.56 and a beta of 1.66. The stock’s fifty day moving average price is $0.39 and its 200 day moving average price is $0.57. Citius Pharmaceuticals has a 1-year low of $0.11 and a 1-year high of $1.07.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CTXR. Armistice Capital LLC purchased a new stake in Citius Pharmaceuticals during the 2nd quarter worth about $5,928,000. Vanguard Group Inc. boosted its holdings in Citius Pharmaceuticals by 1.5% in the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after purchasing an additional 104,889 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Citius Pharmaceuticals by 14.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after buying an additional 232,656 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at $118,000. Finally, Wealth Advisory Solutions LLC grew its position in shares of Citius Pharmaceuticals by 33.1% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after buying an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.